Journey Medical Corp 8-K

What Happened Journey Medical Corporation (DERM) filed an 8-K on June 26, 2026 reporting results of its 2026 Annual Meeting held June 24, 2026 (virtual). Stockholders representing 16,145,526 shares of Common Stock and 6,000,000 shares of Class A Common Stock (together 81% of the 27,346,466 shares entitled to vote) were present in person or by proxy. The meeting approved two proposals: (1) election of six directors to serve until the 2027 annual meeting, and (2) ratification of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Record date: April 28, 2026. Total outstanding eligible shares: 21,346,466 Common and 6,000,000 Class A Common (Class A shares carry 3.91 votes each per the charter).
• Directors elected (vote tallies: For / Withheld / Broker Non-Votes):
  • Lindsay A. Rosenwald, M.D.: 32,559,583 / 551,063 / 6,515,971
  • Claude Maraoui: 32,972,638 / 138,008 / 6,515,971
  • Neil Herskowitz: 31,728,709 / 1,381,937 / 6,515,971
  • Justin Smith: 32,873,028 / 237,618 / 6,515,971
  • Miranda Toledano: 32,513,215 / 597,431 / 6,515,971
  • Michael Pearce: 32,972,865 / 137,781 / 6,515,971
• Auditor ratification (Proposal 2): KPMG LLP ratified — For: 39,374,407; Against: 50,168; Abstentions: 202,042.

Why It Matters The meeting confirms the Company’s board slate and maintains continuity in external audit oversight by ratifying KPMG. For investors, these outcomes mean no immediate governance changes were approved that would affect company strategy or audit arrangements; the elected directors will oversee company decisions through the 2027 annual meeting and KPMG will handle the 2026 audit. The 8-K contains the official vote counts and quorum/record-date details for shareholders tracking governance and oversight.